Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies.
Kyle W SingletonAlyx B PorterLeland S HuSandra K JohnstonKamila M BondCassandra R RickertsenGustavo De LeonScott A WhitmireKamala R Clark-SwansonMaciej M MrugalaKristin R SwansonPublished in: Neuro-oncology advances (2020)
DG has significant meaning in recurrent therapy as a metric of treatment response, even in the context of anti-angiogenic therapies. This provides further evidence supporting the use of DG as an adjunct response metric that quantitatively connects treatment response and clinical outcomes.